Seres Therapeutics Inc., of Cambridge, Mass., is presenting new data for SER-109, a microbiome candidate in phase III development, at the IDWeek 2018 conference in San Francisco. The findings, highlighted in two presentations, provide support for SER-109 as a potential new treatment option for individuals suffering from recurrent Clostridium difficile infection.